Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OT-82 in Relapsed or Refractory Lymphoma
NCT03921879Phase 1Unknown
- Sponsor
- OncoTartis, Inc.
- Start
- Jul 2019
- Primary completion
- Apr 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of OT-82 in non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) (2 arms), sponsored by OncoTartis, Inc. Primary endpoints: Occurrence of Dose Limiting Toxicities, Overall Response Rate and 3 more. Status: unknown.
02
Drugs
OT-82
03
Conditions
non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT03921879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03921879.